Vicore Pharma: Clinical Study in New Indication (Pulmonary Arterial Hypertension) Announced - Redeye

Earlier today, Vicore announced that it will add a new indication for C21, the rare lung disease pulmonary arterial hypertension (PAH), and start a proof-of-concept study by late 2022. PAH has a significant unmet medical need, as today’s treatments do not change the underlying disease, and Vicore states that promising pre-clinical data and the vascular effect showed in the mechanistic systemic sclerosis trial together call for further research into the indication. We are encouraged by the move and see a solid rationale. Vicore will host an R&D day tomorrow where we expect to learn more about the study and upcoming strategy.

Länk till analysen i sin helhet: https://www.redeye.se/research/835919/vicore-pharma-clinical-study-in-new-indication-pulmonary-arterial-hypertension-announced?utm_source=finwire&utm_medium=RSS